

Figure S1. Expression of SD-4 and DC-HIL binding by other CTCL lines

MyLa or SeAx cells were examined by flow cytometry for expression of SD-4 and binding to DC-HIL-Fc. Control and experimental staining are represented as gray and open histograms, respectively.



Figure S2. SD-4 expression is confined to CD26^{-}/CD4^{+} cells in SS patients with high tumor burden

PBMCs isolated from SS patients with high tumor burdens (Pt #3, Pt #6, and a patient with Vβ5.1) or a normal donor (ND) were stained with PE-anti-SD-4, FITC-anti-CD4, and APC-anti-CD26 Ab, and subjected to flow cytometric analysis. Top panels show expression of SD-4 vs. CD4, and bottom panels show expression of SD-4 vs. CD26 on CD4^{+} cells (gated).



Figure S3. No significant expression of type I and II TGF-β receptors on CTCL lines
(A) Total RNA isolated from CTCL lines (HH, MJ, and HuT-78), non-CTCL lines (Jurkat and Molt-4), or normal $CD4^+$ T cells activated *in vitro* (CD4 T) was examined by RT-PCR for expression of mRNA for TGF-β1, the type I (R-I) and II (R-II) receptors, and β-actin. (B and C) CTCL lines were untreated (B) or permeabilized (C) prior to staining with anti-TGF-β RII Ab. Expression was measured by flow cytometry. All 3 CTCL cell lines did not express TGF-β RI mRNA. MJ are negative for TGF-β RII mRNA; HH and HuT-78 cells express TGF-β RII mRNA, but not on the surface.



Figure S4. TGF-β–treated normal CD4$^+$ T cells do not inhibit allogeneic anti-CD3 response

Varying cell numbers of PBMCs from Pt #6 or normal CD4$^+$ T cells (NT) were incubated with/without TGF-β1, treated with mitomycin C, and co-cultured with CD4$^+$ T cells (2 × 10^5 cells) isolated from an allogenic healthy donor in the presence of anti-CD3 Ab. After culturing for 3 d, T-cell activation was measured by ^{3}H-thymidine incorporation.



Figure S5. TGF-β–coating augments ability of SS cells to inhibit syngeneic anti-CD3 response

$CD4^+$ T cells were isolated from PBMCs of Pt #7 containing $CD4^{low}$ and $CD4^{high}$ subpopulations (Fig. 1F), incubated with biotinylated anti–SD-4 Ab/streptavidin-beads, and then applied to a column. A column-pass through ($SD\text{-}4^-/CD4^+$ T cells) and a column-bound ($SD\text{-}4^+/CD4^+$) fraction (Fr) was collected and analyzed by flow cytometry for expression of SD-4 and CD4. Data of column-bound fraction is shown (A). (B) $SD\text{-}4^+/CD4^+$ cells were coated similarly with/without TGF-β1, treated with mitomycin C, and then co-cultured for 3 d with $SD\text{-}4^-/CD4^+$ cells (2×10^5 cells/well, as responder) in the presence of anti-CD3 Ab (1 μg/ml). Proliferation was measured by ^{3}H-thymidine incorporation.